

1 **Genomic surveillance, characterisation and intervention of a**
2 **carbapenem-resistant *Acinetobacter baumannii* outbreak in**
3 **critical care**

4

5 Leah W. Roberts^{1,2,3*}, Brian M. Forde^{1,2}, Trish Hurst^{4,6,7}, Weiping Ling⁴, Graeme R.
6 Nimmo⁵, Haakon Bergh⁵, Narelle George⁵, Krispin Hajkowitz⁷, John F McNamara⁴,
7 Jeffrey Lipman^{4,8}, Budi Permana^{1,2*}, Mark A. Schembri^{1,2}, David Paterson^{4,7}, Scott A.
8 Beatson^{1,2*}, Patrick N. A. Harris^{2,4,5*}

9

10 ¹School of Chemistry and Molecular Biosciences, University of Queensland,
11 Brisbane, QLD, Australia.

12 ²Australian Infectious Disease Research Centre, University of Queensland, Brisbane
13 QLD, Australia.

14 ³EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.

15 ⁴The University of Queensland, Faculty of Medicine, UQ Centre for Clinical
16 Research, Brisbane, QLD, Australia.

17 ⁵Pathology Queensland, Central Laboratory, Brisbane, QLD, Australia.

18 ⁶Infection Monitoring and Prevention Service, Royal Brisbane and Women's
19 Hospital, Herston, Queensland, Australia.

20 ⁷Unit of Infectious Diseases, Royal Brisbane and Women's Hospital, Herston,
21 Queensland, Australia.

22 ⁸Nimes University Hospital, University of Montpellier, Nimes, France.

23

24

25 *Corresponding authors:

26 **Leah Roberts: (leah@ebi.ac.uk)**

27 EMBL-EBI

28 Wellcome Genome Campus

29 Hinxton, Cambridge, United Kingdom

30

31 **Scott Beatson (scott.beatson@uq.edu.au)**

32 School of Chemistry and Molecular Biosciences

33 University of Queensland

34 St Lucia, Brisbane, Queensland, Australia

35

36 **Patrick Harris (p.harris@uq.edu.au)**

37 University of Queensland Centre for Clinical Research (UQCCR)

38 Royal Brisbane and Women's Hospital

39 Herston, Brisbane, Queensland, Australia

40

41

42 **One sentence summary:**

43 By using prospective whole genome sequencing (WGS) combined with detailed

44 reporting and environmental metagenomic sequencing, we were able to fully

45 characterize a polymicrobial outbreak in critical care by determining the main causative

46 outbreak strain (an ST1050 carbapenem-resistant *Acinetobacter baumannii*) and

47 identifying key reservoirs in the environment to resolve the outbreak.

48

49

50 **Abstract:**

51 Infections caused by carbapenem-resistant *Acinetobacter baumannii* (CR-Ab) have
52 become increasingly prevalent in clinical settings and often result in significant
53 morbidity and mortality due to their multidrug resistance (MDR). Here we present an
54 integrated whole genome sequencing (WGS) response to a polymicrobial outbreak in a
55 Brisbane hospital between 2016-2018. 28 CR-Ab (and 21 other MDR Gram negative
56 bacilli) were collected from Intensive Care Unit and Burns Unit patients and sent for
57 WGS with a 7-day turn-around-time in clinical reporting. All CR-Ab were sequence
58 type (ST)1050 and within 10 single nucleotide polymorphisms (SNPs) apart, indicative
59 of an ongoing outbreak, and distinct from historical CR-Ab isolates from the same
60 hospital. Possible transmission routes between patients were identified on the basis of
61 CR-Ab and *K. pneumoniae* SNP profiles. Continued WGS surveillance between 2016
62 to 2018 enabled suspected outbreak cases to be refuted, but a resurgence of the outbreak
63 CR-Ab mid-2018 in the Burns Unit prompted additional screening. Environmental
64 metagenomic sequencing identified the hospital plumbing as a potential source.
65 Replacement of the plumbing and routine drain maintenance resulted in rapid resolution
66 of the secondary outbreak and significant risk reduction with no discernable
67 transmission in the Burns Unit since. Here we demonstrate implementation of a
68 comprehensive WGS and metagenomics investigation that resolved a persistent CR-Ab
69 outbreak in a critical care setting.

70

71

72 **Keywords:** carbapenem resistance, *Acinetobacter baumannii*, CR-Ab, whole genome
73 sequencing, WGS, intensive care unit, burns ward, metagenomics, genomics,
74 surveillance

75 **Introduction:**

76 Hospital outbreaks of multi-drug resistant Gram-negative pathogens present great risk
77 to patients and are costly(1, 2). Whole genome sequencing (WGS) has been proposed
78 as an effective tool to support infection control responses to emerging outbreaks within
79 the healthcare environment, but barriers exist to the effective implementation into
80 clinical practice(3).

81

82 *Acinetobacter baumannii* has emerged over recent decades as a major nosocomial
83 pathogen(4). Its capacity to develop or acquire resistance to multiple antibiotic classes,
84 in addition to intrinsic resistance to desiccation and disinfectants, contributes to
85 persistence of *A. baumannii* in the hospital environment(5, 6). It has frequently been a
86 cause of nosocomial outbreaks, particularly in the critical care setting(7-9). *A.*
87 *baumannii* are often resistant to multiple antibiotic classes and the global incidence of
88 extensively-drug resistant (XDR) or even pan-drug resistant (PDR) strains has been
89 increasing(10-12). Carbapenem-resistant *A. baumannii* (CR-Ab) have been seen at
90 high prevalence in several areas, particularly in the Asian-Pacific region, Latin America
91 and the Mediterranean(13). Carbapenem resistance in *A. baumannii* usually arises from
92 the acquisition of genes encoding carbapenemases, particularly OXA-type
93 carbapenemases (e.g. OXA-23), and may be associated with high mortality in
94 vulnerable patients(14).

95

96 Here we describe a large outbreak of CR-Ab, and other co-infecting MDR Gram-
97 negative pathogens, occurring within an Intensive Care Unit (ICU) and burns facility.
98 Incorporation of whole genome sequencing (WGS) in real-time facilitated rapid
99 characterisation of this complex polymicrobial outbreak, provided a detailed

100 understanding of transmission pathways and helped to direct a successful infection
101 control response.

102

103 **Case study:**

104 A 25-year old patient with extensive burn injuries was retrieved from an overseas
105 healthcare facility. As per infection control protocols, the patient was placed on contact
106 precautions and provided a single room. Initial nasal and rectal screening swabs were
107 negative for MDR pathogens, including CR-Ab. An extended-spectrum beta-lactamase
108 (ESBL)-producing *Klebsiella pneumoniae* was isolated from the patient's respiratory
109 secretions on day 4, and within 24-hours a similar organism was isolated from blood
110 cultures. Repeated collection of blood cultures demonstrated a polymicrobial culture
111 with ESBL-producing *K. pneumoniae*, CR-Ab and *Pseudomonas aeruginosa* on day 6,
112 that tested susceptible to all first line agents. Over the following days, CR-Ab was also
113 isolated from numerous clinical specimens, including a femoral line tip, endotracheal
114 aspirates, rectal swabs, wound swabs and operative specimens collected from debrided
115 tissue. Blood cultures repeatedly grew CR-Ab, (day 15 and 45 of admission), with the
116 emergence of colistin resistance when tested by Etest (MIC 32 $\mu\text{g.mL}^{-1}$) on day 45.
117 *Serratia marcescens* was co-cultured in blood on day 15 and was also grown from
118 respiratory secretions and wounds swabs.

119 Over the next 5 months in 2016, 18 additional patients within the same Intensive Care
120 Unit (ICU) area were also found to be colonized or infected with phenotypically similar
121 CR-Ab, *K. pneumoniae*, *S. marcescens* and/or *P. aeruginosa*. This included CR-Ab
122 colonized cases identified in patients discharged from the ICU to the Burns Unit or
123 other surgical wards throughout the hospital, and eventually patients admitted to the
124 Burns Unit. The final CR-Ab case was identified several weeks later in a patient

125 discharged from the Burns Unit and transferred to a hospital in a remote part of
126 Queensland. An outbreak investigation team was constituted as soon as it was suspected
127 that an outbreak of CR-Ab had occurred within the ICU and the use of WGS for strain
128 characterization was initiated.

129

130 **Results:**

131

132 WGS predicted likely transmission pathways and ruled out non-outbreak cases

133 Between May to August 2016, a total of 55 isolates were recovered from 22 patients
134 (see supplementary data 1). These isolates included *A. baumannii*, *K. pneumoniae*, *S.*
135 *marcescens*, *E. cloacae* and *P. aeruginosa*. Species typing and antibiogram analysis
136 alone were insufficient to determine clonal relationships between these isolates. As
137 such, we used WGS to establish the relationship between isolates and predict patient
138 transmission based on SNP accumulation.

139

140 We applied WGS in real-time over the course of the outbreak. Four reports aimed at
141 communicating genomic analyses to infection control and other clinical staff at RBWH
142 were delivered during the primary outbreak (June 22, July 15, Aug 2 and Aug 29). We
143 managed on average a one-week turn-around time between receiving the isolates and
144 presenting a finalised report, which consistent of [i] a front page overview of the
145 analysis and key outcomes/interpretations conveyed as short bullet points, [ii] detailed
146 analysis and diagrams on the internal pages, and [iii] method descriptions (see
147 supplementary methods and results 1). Actual time between receipt of sequencing data
148 and reporting was 8-72 hours depending on the complexity of analyses with
149 supplementary interim reports and regular academic-clinical partner meetings

150 necessary to communicate our comparative genomic analyses and help shape the
151 content of the final reports (see supplementary reports 1 and 2 for example reports from
152 June 22 and Aug 29, respectively).

153

154 The presumed index patient admitted in early May 2016 was identified with ST1050
155 CR-Ab, ST515 *K. pneumoniae*, ST979 *P. aeruginosa* and *S. marcescens*. Using WGS,
156 we found that 16 of the 21 patients admitted following the index patient had bacterial
157 infections related to either the ST1050 CR-Ab or the ST515 *K. pneumoniae*.
158 Transmission direction based on the accumulation of SNPs was inferred in patients 10,
159 11, 13, 14, 15, 16 and 17 (Figure 1A, as indicated by lines with arrows). CR-Ab isolates
160 from the first 9 patients (and patient 12) were identical based on core SNPs, making
161 inference of patient transmission impossible using SNPs alone. However, when
162 combined with SNP information from *K. pneumoniae* isolates, it was possible to infer
163 co-transmission of *K. pneumoniae* and CR-Ab from the index patient to patient 6
164 (Figure 1 and supplementary methods and results 1).

165

166 Strains of *S. marcescens* and *P. aeruginosa* specific to the index patient were not found
167 in other patients (see supplementary material). Two patients had unrelated *S.*
168 *marcescens* and *P. aeruginosa* isolates (patients 13 and 6, respectively). Transmission
169 of the unrelated *P. aeruginosa* isolate from patient 6 to another patient in the ICU ward
170 (denoted patient V) was detected. Patient V was also found to have an *Enterobacter*
171 *cloacae* isolate (later identified as *Enterobacter hormaechei* by WGS) identical to that
172 identified in a 2015 outbreak from the same hospital(15). This patient also carried an
173 additional carbapenem-sensitive *E. cloacae* (*bla*_{IMP-4} negative) that was unrelated to the
174 carbapenem-resistant isolate.

175

176 Over the course of the outbreak, each species carried by the index patient acquired
177 additional antibiotic resistance mechanisms, via mutations or plasmid gain (Figure 1
178 and supplementary methods and results 1).

179

180 An additional CR-Ab was isolated in September 2016 from a patient in a Regional
181 Queensland (QLD) hospital who had previously been admitted to the Brisbane ICU
182 (patient 18, isolate MS14438). Analysis of this isolate found that it was closely related
183 to isolates from the initial outbreak between May to August 2016.

184

185 Extensive environmental swabbing throughout the ICU and Burns Unit was conducted
186 on the 16th of June 2016, targeting patient bedrooms as well as high-touch areas (e.g.
187 Nurse keyboards, trolley, door handles). However, no bacterial species related to the
188 CR-Ab outbreak were detected in the environment based on traditional culture methods
189 using chromogenic agar.

190

191 The outbreak CR-Ab was likely imported into the hospital ICU

192 29 CR-Ab isolates related to the ongoing outbreak were collected from 18 patients
193 Between May-September 2016. All were found to be ST1050 (global clone [GC] 2)
194 and less than 10 SNPs different (fig. S2). Three carbapenem-sensitive *A. baumannii*
195 isolated at the same time were found to be different sequence types and unrelated to the
196 outbreak. Comparison of the outbreak ST1050 CR-Ab isolates to historical CR-Ab
197 isolates collected between 2000-2016 from the hospital found no close relationship,
198 indicating that the CR-Ab had likely been introduced into the hospital with the index
199 patient (fig. S3).

200

201 All ST1050 CR-Ab isolates related to the index were found to be extensively resistant
202 to carbapenems, β -lactams, cephalosporins, aminoglycosides, and quinolones (Table
203 1). Resistance to colistin appeared in three isolates from the index patient and was
204 mediated by two independent SNP acquisitions in the sensor kinase gene *pmrB* (causing
205 the amino acid changes T235I in MS14413 and its descendant MS14402, and R263C
206 in MS14407). Antibiotic resistance genes were conserved between all isolates, and
207 included β -lactamases (such as *bla*_{OXA-23} and *bla*_{OXA-66}), streptomycin resistance genes
208 (*strA* and *strB*), and aminoglycoside resistance genes (*aph(3')*-*Ic*, *aadA1* and the
209 methylase *armA*). Finally, a single SNP was found to result in the reversion of a
210 nonsense mutation in a putative type 3 filamentous fimbriae gene (*filB*). This SNP was
211 identified in the majority of CR-Ab isolates taken after the 4th of July 2016 and appears
212 to have arisen independently multiple times in the *A. baumannii* lineage (supplementary
213 methods and fig. S4).

214

215 PacBio sequencing of CR-Ab reveals context of resistance genes and mobile elements

216 Complete sequencing of a reference CR-Ab isolate (MS14413) from the index patient
217 using long-read sequencing provided a high-quality reference and allowed
218 contextualization of the antibiotic resistance genes (as well as other mobile genetic
219 elements) within the genome. Assembly of the ST1050 CR-Ab reference genome
220 revealed a 4,082,498 bp chromosome with no plasmids. *strA*, *strB* and *sul2* resided
221 within a novel AbGRI1 resistance island most closely related to the *A. baumannii* strain
222 CBA7 (GenBank:NZ_CP020586.1) isolated from Korea in 2017 (fig. S5). The CR-Ab
223 isolates also carried Tn6279 (also known as AbGRI3-2), which encompassed a large
224 number of resistance genes including *mph(E)* and *msr(E)* (macrolide resistance) and

225 the methylase gene *armA* (gentamicin resistance) (fig. S6). Resistance to carbapenems
226 in these CR-Ab isolates was likely driven by the presence of two copies of *bla*_{OXA-23}
227 residing in separate Tn2006 transposons within the chromosome. An IS*Aba1* insertion
228 sequence upstream of the chromosomal *ampC* gene was also detected, which has
229 previously been shown to enhance cephalosporin resistance(16).

230

231 Long read sequencing also revealed a KL12 capsule (K) locus, which shares 97%
232 nucleotide identity to the capsule region found in the GC1 *A. baumannii* strain D36
233 (GenBank:NZ_CP012952.1) (fig. S7). However, the *wzy* gene (a polymerase required
234 for capsular polysaccharide biosynthesis) within the capsule locus was interrupted by
235 an IS*Aba125* insertion sequence in all CR-Ab isolates. Further comparative analysis
236 found a portion of the capsule locus in MS14413 to share 99% nucleotide identity to
237 the capsule from *A. baumannii* strain BAL_097 (GenBank: KX712116), which carries
238 a *wzy* gene at the beginning of the capsule region. This unusual gene placement also
239 appears in MS14413, and likely complements the loss of the internal *wzy* gene (Figure
240 2). The high nucleotide identity at this region also indicates possible recombination.
241 Overlapping the capsule (K) region in MS14413 (and some other patient 1 CR-Ab
242 isolates) is a large 41,375 kb tandem duplication, encompassing Tn2006 (resulting in 3
243 chromosomal copies of this transposon) and is further discussed in the Supplementary
244 results (Figure 2).

245

246 Whole genome shotgun metagenomics detects CR-Ab in hospital environment

247 Ongoing surveillance was conducted using WGS following the initial outbreak. Despite
248 continual environmental cleaning and routine swabbing, the outbreak CR-Ab strain
249 persisted through to September 2018 (Figure 3). Swabs collected from surfaces within

250 the ICU and Burns Unit (e.g. handles, tables, shelves, computer equipment) in 2016
251 and 2017 were unable to detect CR-Ab in the environment and did not yield enough
252 DNA for direct metagenomic sequencing (data not shown).

253

254 Due to 11 new cases of CR-Ab detected between May to September 2018, additional
255 environmental sampling was carried out in the Burns ward environment. Between July
256 to October 2018, areas of presumed high bacterial load (such as floor drains, plumbing,
257 inside burns bath drains, etc.) were targeting for environmental sampling (figure 4). All
258 samples were subjected to culture using traditional methods (on chromogenic media)
259 and direct DNA extraction and shotgun metagenomic sequencing. Of 50 environmental
260 samples, two were culture positive for CR-Ab (R5666 and R5864), while four were
261 positive based on analysis of the metagenomic sequencing data (R5515, R5510, R5863
262 and R5864) (table S4, fig. S11).

263

264 An ST1050 CR-Ab was cultured using traditional methods from the environmental
265 sample R5666, taken from a crack in a toilet seat being used by a patient colonized with
266 the ST1050 CR-Ab. The depth of sequencing obtained from the same environmental
267 sample, however, was not sensitive enough to be able to confidently detect the presence
268 of the CR-Ab in the metagenomic data. The second positive ST1050 CR-Ab culture
269 came from an environmental sample taken from an Antechamber room connected to
270 patient rooms that had previously been colonized with ST1050 CR-Ab (R5864).
271 Parallel metagenomic sequencing was also able to detect this same ST1050 CR-Ab in
272 the environmental sample (Figure 5).

273

274 Additionally, three other samples were found to have ST1050 CR-Ab based on
275 metagenomic sequencing, despite being culture negative using traditional methods
276 (figure 5, table S4). Samples R5515 (burns bath 2 floor trap water sample) and R5510
277 (burns bath 2 bath drain hole [interior]) were both positive for ST1050 CR-Ab. Both
278 samples were taken at the same time from proximal locations, and patients colonized
279 with ST1050 CR-Ab were using the burns bath in question. Samples R5863 was also
280 positive for ST1050 CR-Ab, and was taken from the room previously occupied by a
281 patient known to be colonized with ST1050 CR-Ab.

282

283 Plumbing maintenance program implemented in response to genomic investigation

284 Shotgun metagenomic detection of the outbreak strain in the hospital plumbing
285 provided the evidence base for implementation of a sustainable infection prevention
286 strategy. Consequently, a routine plumbing maintenance program was instituted. Every
287 month, pipes were soaked for 30-minute in sodium hydroxide, with additional soaking
288 and scrubbing of drain plates. Since the implementation of these measures, no further
289 cases of CR-Ab have been detected in the Burns Unit or Intensive Care Unit (ICU)
290 following 28th September 2018. Between December 2018-May 2019, three additional
291 ST1050 cases were detected outside the ICU and Burns Unit and linked to the outbreak
292 via routine surveillance under the Queensland Genomics Healthcare-associated
293 Infections project. One case produced sputum and blood isolates from the same patient
294 while the other two were detected at two different hospitals in South-East Queensland.
295 Periodic environmental surveillance of CR-Ab in drains and plumbing in the Burns unit
296 has been ongoing as of May 2020. No further detection of the outbreak strain has
297 occurred since May 2019 (Fig. S12).

298

299 Significant reduction of risk following interventions

300 A total of 32 CR-Ab cases were recorded over 28 months in the pre-intervention period,
301 compared to 4 CR-Ab cases over 21 months in the post-intervention period. All cases
302 identified at pre-intervention period were admitted to the Burns or Intensive Care Units
303 during their hospitalisation. Conversely, 3 out of the 4 CR-Ab cases detected in the
304 post-intervention period had no obvious epidemiological link to exposure in the Burns
305 and Intensive Care Units. The incidence rate post-intervention was 2 CR-Ab cases per
306 year, significantly reduced from the pre-intervention incidence rate of 13 CR-Ab case
307 per year ($p < 0.001$). The post-intervention CR-Ab incidence rate was reduced by 17%
308 compared to the pre-intervention period (incidence rate reduction=0.17, 95% CI: 0.06-
309 0.47).

310

311 **Discussion**

312 CR-Ab are an increasingly dire threat to global public health. Their proficiency at
313 surviving for long periods of time in environments whilst under antibiotic pressure is
314 largely due to the positive selection of both intrinsic and acquired resistance and
315 survival mechanisms. As such, they present a significant problem in health-care
316 settings, which typically have high antibiotic use as well as a large cohort of vulnerable
317 patients. Understanding the mechanisms behind their resistance and transmission, as
318 well as their possible environmental reservoirs, is key to combating further colonization
319 and infection in hospital settings. Here we present a comprehensive analysis of an
320 outbreak of CR-Ab using isolate and environmental metagenomic sequencing to fully
321 elucidate transmission, determine new cases rapidly and detect possible environmental
322 reservoirs within the hospital.

323

324 Genomics is being rapidly established in clinical settings, particularly in response to
325 outbreaks(17, 18). This is due not only to the higher discriminatory power that WGS
326 provides, but also the complete picture that WGS captures by yielding the entire
327 genome. The current cost and turnaround time for sequencing and analysis also make
328 this type of investigation more feasible in nosocomial settings. In this study, initial
329 sequencing of the outbreak CR-Ab isolates (and associated bacterial species) confirmed
330 an already suspected outbreak, and so despite providing more insight into possible
331 transmission routes, it did not greatly affect the infection control response. However,
332 genomics superseded traditional methods when it came to [i] contextualizing outbreak
333 isolates with previous CR-Ab strains from the hospital (to determine the likely source),
334 and [ii] contextualizing new CR-Ab isolates as they appeared after the initial outbreak
335 to determine whether there was an ongoing problem in the hospital. While having a
336 slightly faster turnaround time, traditional methods alone would not have been able to
337 confidently assess either of these scenarios. Regular meetings and reporting of the
338 genomic results provided the hospital with actionable information and greater insight
339 into the ongoing outbreak. These cross-disciplinary discussions facilitated the
340 communication of complex genomic data into the clinical setting, providing guiding
341 principles for subsequent WGS reporting of multidrug resistant bacterial pathogens at
342 this hospital, and prompting the development of an interactive online visualization for
343 communicating genomic epidemiology data (see movie S1).

344

345 In addition to providing evidence for related isolates, WGS was also a valuable tool for
346 discerning unrelated isolates, in many cases preventing ward or operating theatre
347 closures and mitigating the associated financial costs to the hospital(19, 20). It is
348 plausible that with continued, ongoing sequencing of clinically significant bacteria in

349 high-risk environments (e.g. ICU and Burns Unit) the risk of outbreaks could be
350 reduced if evidence of transmission was detected early. During this study, we were able
351 to detect transmission of an *E. hormaechei* unrelated to the outbreak at hand, but linked
352 to a *bla*_{IMP-4} carbapenemase-producing Enterobacteriaceae (CPE) outbreak from the
353 same hospital the year prior(15). We were also able to identify transmission of an
354 unrelated meropenem-resistant *P. aeruginosa* isolate, highlighting how WGS can
355 detect transmission well before it becomes known to staff. The discovery of four
356 ST1050 outbreak isolates in late 2018 to early 2019 also highlights the importance of
357 early detection and intervention to limit and control spread. These three patients had no
358 exposure to the ICU or Burns Unit at any time during this outbreak, so we can only
359 propose that the environment (i.e. the plumbing) and/or undetected transmission
360 facilitated by other patients or healthcare workers (between the two additional
361 hospitals) as the most likely source. Remarkably, as this manuscript was in preparation,
362 we also discovered the same ST1050 outbreak strain from a patient readmitted to
363 RBWH 18 months after positive blood and sputum cultures. Long-term carriage of *A.*
364 *baumannii* has been observed previously(21). This finding not only implicates
365 discharged patients in the spread between different hospitals but highlights their
366 potential for reintroduction of the outbreak strain into settings where it has been
367 previously eradicated.

368

369 Routine WGS can also lead to a reduction in the costs associated with responding to an
370 established outbreak. A study of a similar outbreak in Brisbane determined the cost per
371 patient related to the outbreak to be six-times higher than unrelated patients(22).
372 However, the feasibility (i.e. access to sequencing facilities and analysis) of routinely
373 sequencing multidrug-resistant organisms is not yet achievable for many hospitals.

374

375 Determining relatedness and transmission using genomics has historically relied on the
376 number of core SNP differences between isolates(23-25). However, this approach has
377 several flaws, including a general lack of consensus on SNP cutoffs and what number
378 defines a related isolate within a particular species, as well as the fact that it largely
379 ignores other genomic differences, such as large insertions, inversion and
380 rearrangements. It also does not account for hypermutators, which we observed in the
381 case of the *K. pneumoniae* isolate MS14418 (see supplementary methods and results
382 1). More recent methods have explored the use of transmission probabilities by taking
383 into account isolation time and species mutation rate(26), but these methods appear
384 more suited to outbreaks spanning large timeframes. Most studies to date that have used
385 SNP distances have used them retrospectively and under research conditions, thereby
386 avoiding the necessity to conform to standardized metrics and allow case-by-case
387 judgments to be made on isolates. Moving forward, translating this approach into
388 standardized clinical settings will likely present several hurdles. In our study, with the
389 exception of the hypermutator strain MS14418 there was no ambiguity using SNP
390 distances to determine relatedness due to the observed low mutation rate. However,
391 because of this, many isolates were unable to be discriminated, with several identical
392 at the core genome level. We were surprised that the initial polymicrobial nature of this
393 outbreak enabled deduction of transmission routes by examining SNP differences
394 between their respective companion *K. pneumoniae* isolates which appeared to have
395 coinfecting with the CR-Ab. However, all of these transmissions were from the index
396 patient and were already recognized by the clinical team. In contrast, the spread of CR-
397 Ab between the ICU and Burns Units in July could be traced to transmission of CR-Ab
398 carrying a discriminatory SNP from the index patient to patient 10 in the Burns Unit

399 with subsequent transmission of CR-Ab to Patient 11, 14 and 17 in the Burns Unit and
400 Patient 13 in the ICU (Figure 1). Further work into identifying both SNPs and pan-
401 genome markers (such as gain/loss of regions or movement of mobile elements) could
402 assist in further characterizing this outbreak and others.

403

404 Metagenomic sequencing of the environment was able to identify several areas positive
405 for ST1050 CR-Ab. In one case, metagenomic sequencing analysis and traditional
406 culture methods were concordant and both identified the ST1050 CR-Ab. In all other
407 cases, either traditional culture or metagenomic sequencing was able to recover the
408 ST1050 CR-Ab, highlighting the advantage of using both methods during an outbreak.
409 While metagenomic sequencing was able to recover more positive results than the
410 traditional methods, it has several limitations, including the necessity for high bacterial
411 loads (such that there is sufficient starting DNA to sequence) and the increased costs
412 (in our study, we observed that at least 5 Gigabase pairs of sequencing data is required
413 to get a basic amount of depth and sensitivity when looking for specific strains). In
414 future, initial PCR from the environmental DNA targeting a known marker in the
415 outbreak strain could help narrow the candidates for complete metagenomic
416 sequencing. Further work is required to refine these methods and determine an accurate
417 guideline, particularly as it relates to sequencing depth and sensitivity.

418

419 All of the positive sequencing and culture results from the environmental sampling
420 were from areas presently or previously being used by patients colonized with the
421 ST1050 CR-Ab. As such, we cannot be sure that the identified ST1050 CR-Ab was
422 present in these environments prior to colonization, or if it was shed from the patient.
423 Subsequent environmental sampling was carried out after each round of cleaning, and

424 no CR-Ab was detected afterwards. It is most likely that the CR-Ab detected in the
425 environmental reservoirs were shed from the patients, however this result does indicate
426 the ease of transmission of this organism from colonized patients to fomites within the
427 hospital, where they then might transmit to other areas or to hospital staff(27).

428

429 By using WGS to assist in a large outbreak of CR-Ab (and other MDR gram-negative
430 bacilli) we show how genomics can be used to improve rapid response measures and
431 outbreak management, as well as provide in-depth characterization of the outbreak
432 strains to establish a historical database that can be used to guide responses to future
433 outbreaks. We also show how direct sequencing of environmental samples was able to
434 detect evidence of the outbreak strain leading to key changes in infection control policy.

435

436 **Materials and Methods**

437

438 Study setting and patient inclusion

439 Primary isolates were obtained from patients admitted to the Royal Brisbane &
440 Women's Hospital (RBWH), a tertiary referral hospital with 929 beds in South-East
441 Queensland, Australia. The RBWH has a 36 bed ICU providing highly specialist burns
442 care for all of Queensland. The incidence of CR-Ab is low in Australian hospitals(28).

443 All new CR-Ab strains are routinely stored in the clinical laboratory for future
444 reference. For the outbreak investigation, any patient admitted to the RBWH who
445 cultured CR-Ab from any clinical or screening specimen from May to August 2016 was
446 identified as a case and included in the primary outbreak analysis. Any CR-Ab cases
447 during the outbreak period were also included to determine if plasmid-mediated
448 resistance and dissemination was relevant, with any MDR Gram-negative bacilli

449 (including ESBL-producing *K. pneumoniae*, carbapenem-resistant *S. marcescens* or
450 carbapenem-resistant *P. aeruginosa*) prospectively collected for further genomic
451 analysis. Overall these included 28 CR-Ab, 3 carbapenem-sensitive *A. baumannii*, 10
452 *K. pneumoniae*, 7 *P. aeruginosa*, 4 *S. marcescens* and 3 *Enterobacter cloacae* (the *E.*
453 *cloacae* were isolated in relation to a previous outbreak in the same hospital(15)).
454 Stored CR-Ab isolates from a previous outbreak in 2006(6), as well as other sporadic
455 cases imported from overseas to the RBWH during 2015/2016 (prior to the outbreak)
456 were included for further analysis. These included 17 historical CR-Ab isolates from
457 earlier in 2016 (n=3), 2015 (n=2) and between 2000-2006 (n=12). *A. baumannii*
458 identified from the outbreak until mid-2018 were also included in the analysis during
459 continued surveillance and infection control monitoring. These included 3 carbapenem-
460 sensitive *A. baumannii* and 19 CR-Ab isolates. A complete list of all isolates is provided
461 in supplementary data 1.

462

463 Antimicrobial susceptibility testing

464

465 All bacterial isolates were identified by matrix-assisted laser desorption/ionization
466 mass spectrometry (MALDI-TOF) (Vitek MS; bioMérieux, France). Antimicrobial
467 susceptibility testing was carried out using Vitek 2 automated AST-N426 card
468 (bioMérieux). For the first 8 sequential CR-Ab isolates, additional susceptibility testing
469 was undertaken using Etest to determine MICs for meropenem, imipenem, colistin,
470 tigecycline, fosfomycin, amikacin, sulbactam, doxycycline and ceftolozane/tazobactam,
471 with disk diffusion to determine susceptibility to aztreonam and ceftazidime/avibactam.
472 Carbapenemase activity was assessed by the use of the Carba-NP test (RAPIDEC;
473 bioMérieux) and screened for the presence of common carbapenemases found in

474 Enterobacteriaceae using an in-house multiplex real-time PCR (that targets NDM, IMP-
475 4-like, KPC, VIM and OXA-48-like carbapenemases). Once it became clear that all
476 the outbreak strains had an identical antibiogram, susceptibility testing was confined to
477 the Vitek 2 automated AST-N426 panel with MICs to tigecycline, doxycycline and
478 colistin determined by Etest (as the only susceptible agents).

479

480 Bacterial culturing and genomic DNA extraction

481 All isolates were grown on horse blood agar at 37°C overnight. For all historical and
482 outbreak isolates collected between May-September of 2016, colonies were scraped
483 from plates and resuspended in 5 mL Luria Bertani (LB) broth. 1.8 mL of resuspension
484 was use for DNA extraction using the UltraClean® Microbial DNA Isolation Kit (MO
485 BIO Laboratories) as per manufacturer's instructions. All isolates collected after
486 September 2016 were extracted using the DSP DNA Mini Kit on the QIASymphony SP
487 (Qiagen).

488

489 Isolate whole genome sequencing (WGS)

490 Illumina WGS of suspected outbreak patient isolates and historical CR-Ab isolates was
491 performed in four batches of between 10 and 18 samples between June and August
492 2016 at the Australian Centre for Ecogenomics (ACE), The University of Queensland
493 (see supplementary methods and results 1). One CR-Ab isolate (MS14413) and one *K.*
494 *pneumoniae* isolate (MS14393) were selected for sequencing with Pacific Biosciences
495 (PacBio) Single Molecule Real-Time (SMRT) sequencing on an RSII machine (see
496 supplementary methods and results 1). Subsequent Illumina WGS was carried out at
497 Queensland Forensic Scientific Services (QFSS) (see supplementary methods and
498 results 1).

499 Quality control and assembly of WGS data

500 Illumina raw reads were checked for contamination using Kraken(29) v0.10.5-beta and
501 quality using FastQC v0.11.5 (www.bioinformatics.babraham.ac.uk/projects/). Raw
502 reads were filtered for reads less than 80 bp and quality score less than 5 using Nesoni
503 clip v0.130 (<https://github.com/Victorian-Bioinformatics-Consortium/nesoni>). Some
504 reads required further hard trimming with Nesoni clip (10 bp from start, 40 bp from
505 end). Isolates were assembled using SPAdes(30) v3.6.0 at default settings. Contigs less
506 than 10x coverage were removed using a custom script. Assembly metrics were
507 checked for quality using Quast(31) v4.3 (see supplementary data 1). Details of the
508 PacBio genome assembly and annotation can be found in the supplementary methods
509 (supplementary methods and results 1).

510

511 Genomic analysis and clinical reporting

512 Between June and August 2016, four reports of detailed bioinformatic analyses were
513 prepared in response to available Illumina data for *A. baumannii*, *K. pneumoniae*, *P.*
514 *aeruginosa*, *S. marcescens* and *Enterobacter cloacae* patient isolates. Comparative
515 genome analysis using variant calling, phylogenetic reconstruction, transmission
516 pathway prediction, multilocus sequence typing (MLST) resistance gene prediction and
517 plasmid characterization used in the clinical reports are given in supplementary
518 methods (see supplementary methods and results 1). For subsequent analyses of the
519 final genome dataset updated or alternative software was used as described below.

520

521 Core single nucleotide polymorphisms (SNPs) were identified using Snippy(32)
522 (v4.3.6) at default settings and trimmed reads against the complete chromosomes for
523 MS14413 (CR-Ab) and MS14393 (*K. pneumoniae*). Parsnp (v1.2) (at default with “-c”

524 flag) was used to visualize phylogenetic relatedness between the outbreak CR-Ab and
525 the historical *A. baumannii* isolates. Multilocus sequence typing (MLST) was
526 performed using mlst(33) v2.6 (<https://github.com/tseemann/mlst>) against the draft
527 assemblies. The Oxford MLST scheme was used for the CR-Ab isolates(34).
528 Resistance genes were identified using Abricate(35) v0.6 against the ResFinder
529 database(36) (accessed August 18th, 2017). Abricate was also used to determine
530 plasmid types using the PlasmidFinder database(37) (accessed August 18th, 2017).
531 Comparative analyses were completed using the Artemis Genome browser and the
532 Artemic Comparison Tool (ACT). Figures were constructed using EasyFig(38),
533 BRIG(39) and FigTree(40).

534

535 Metagenomic sequencing and analysis

536 Metagenomic sequencing of environmental samples and analysis was conducted as
537 described previously(15). Briefly, swab and water samples from the ICU and Burns
538 Unit were collected in July 2018. DNA was extracted using the Qiagen DNeasy
539 Powersoil extraction kit and sequenced at the Australian Centre for Ecogenomics on an
540 Illumina NextSeq500.

541

542 All samples were screened for species using Kraken(29) v1.0 and resistance genes
543 using SRST2(41) v0.2.0 against the ARG-ANNOT(42) database. Mash(43) v1.1.1 was
544 used at default settings to screen Illumina reads for each samples against our reference
545 CR-Ab sketch (MS14413). Samples that shared $\geq 90\%$ of hashes were mapped to the
546 reference sequence. Mapped reads were parsed and *de novo* assembled using
547 SPAdes(30) v3.11.1 for MLST analysis using mlst(33) v2.16.2 and nucleotide
548 comparison using ACT(44) and BRIG(39).

549

550 Risk reduction assessment

551 We aimed to estimate the reduced risk of patient colonization following the
552 identification of ST1050 CR-Ab by environmental metagenomic sequencing and the
553 initiation of enhanced decontamination of hospital plumbing. The incidence rate of CR-
554 Ab was measured pre-intervention and post-intervention. The point of intervention was
555 defined as the targeted initiation of routine plumbing maintenance program within the
556 Burns and Intensive Care units in August 2018. The intervention was expected to
557 generate immediate results with no lag time. The pre-intervention period was defined
558 as May 2016 to August 2018 and post-intervention period as September 2018 to May
559 2020. All CR-Ab cases recorded in the hospital during these periods were included.
560 Patients admitted to the Burns and Intensive Care units underwent standard clinical
561 swabbing for surveillance and laboratory method for testing did not change over the
562 study period. Statistical analyses were performed on Rv3.5.1.

563

564

565

566

567

568

569

570

571

572

573

574 **Supplementary Materials:**

575 **Supplementary methods and results 1** (supplementary_methods_and_results_1.pdf):

576 *Supplementary results and methods*: additional methods and supplementary results to
577 the main text.

578 Supplementary data 1 (supplementary_data_1.xlsx): *Strain list*: A list of all strains
579 analysed in this study, with their accessions, assembly metrics and associated metadata.

580 Supplementary report 1 (supplementary_report_1.pdf): *First genomic report*: original
581 genomic report on first batch of WGS data delivered June 22, 2016 (redacted for
582 privacy).

583 Supplementary report 2 (supplementary_report_2.pdf): *Fourth genomic report*:
584 original clinical report on fourth batch of WGS data delivered August 29, 2016
585 (redacted for privacy), annotated to highlight alterations to report design in consultation
586 with clinical staff.

587 Movie S1 (supplementary_movie_1.mp4): *Communication of outbreak with HAIviz*:
588 video of outbreak progression produced using Healthcare-Associated Infection
589 visualization tool (<http://HAIviz.beatsonlab.com>), an interactive web-based
590 visualization tool designed to communicate infectious disease genomic data from local
591 outbreaks to healthcare professionals. The dashboard shows outbreak timeline, a local
592 map, patient locations, predicted transmission links and the genetic relationships of
593 isolates based on WGS data.

594

595

596

597

598

599 References:

600

- 601 1. J. A. Otter *et al.*, Counting the cost of an outbreak of carbapenemase-
602 producing Enterobacteriaceae: an economic evaluation from a hospital
603 perspective. *Clin Microbiol Infect* **23**, 188-196 (2017).
- 604 2. M. C. Cruickshank M, Reducing harm to patients from healthcare
605 associated infections: an Australian infection prevention and control
606 model for acute hospitals. . *Sydney: Australian Commission on Safety and*
607 *Quality in Health Care.*, (2009).
- 608 3. C. A. Gilchrist, S. D. Turner, M. F. Riley, W. A. Petri, Jr., E. L. Hewlett, Whole-
609 genome sequencing in outbreak analysis. *Clin Microbiol Rev* **28**, 541-563
610 (2015).
- 611 4. A. Y. Peleg, H. Seifert, D. L. Paterson, *Acinetobacter baumannii*: emergence
612 of a successful pathogen. *Clin Microbiol Rev* **21**, 538-582 (2008).
- 613 5. M. Denton *et al.*, Role of environmental cleaning in controlling an
614 outbreak of *Acinetobacter baumannii* on a neurosurgical intensive care
615 unit. *J Hosp Infect* **56**, 106-110 (2004).
- 616 6. M. Doidge *et al.*, Control of an outbreak of carbapenem-resistant
617 *Acinetobacter baumannii* in Australia after introduction of environmental
618 cleaning with a commercial oxidizing disinfectant. *Infect Control Hosp*
619 *Epidemiol* **31**, 418-420 (2010).
- 620 7. S. H. Wang *et al.*, Healthcare-associated outbreak due to pan-drug
621 resistant *Acinetobacter baumannii* in a surgical intensive care unit. *J Hosp*
622 *Infect* **53**, 97-102 (2003).
- 623 8. R. Valencia *et al.*, Nosocomial outbreak of infection with pan-drug-
624 resistant *Acinetobacter baumannii* in a tertiary care university hospital.
625 *Infect Control Hosp Epidemiol* **30**, 257-263 (2009).
- 626 9. M. del Mar Tomas *et al.*, Hospital outbreak caused by a carbapenem-
627 resistant strain of *Acinetobacter baumannii*: patient prognosis and risk-
628 factors for colonisation and infection. *Clin Microbiol Infect* **11**, 540-546
629 (2005).
- 630 10. J. Nowak *et al.*, High incidence of pandrug-resistant *Acinetobacter*
631 *baumannii* isolates collected from patients with ventilator-associated
632 pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical
633 trial. *J Antimicrob Chemother* **72**, 3277-3282 (2017).
- 634 11. R. Xie, X. D. Zhang, Q. Zhao, B. Peng, J. Zheng, Analysis of global prevalence
635 of antibiotic resistance in *Acinetobacter baumannii* infections disclosed a
636 faster increase in OECD countries. *Emerg Microbes Infect* **7**, 31 (2018).
- 637 12. C. L. Jones *et al.*, Fatal outbreak of an emerging clone of extensively drug-
638 resistant *Acinetobacter baumannii* with enhanced virulence. *Clin Infect*
639 *Dis* **61**, 145-154 (2015).
- 640 13. W. Kamolvit, H. E. Sidjabat, D. L. Paterson, Molecular Epidemiology and
641 Mechanisms of Carbapenem Resistance of *Acinetobacter* spp. in Asia and
642 Oceania. *Microb Drug Resist* **21**, 424-434 (2015).
- 643 14. S. Brown, S. Amyes, OXA (beta)-lactamases in *Acinetobacter*: the story so
644 far. *J Antimicrob Chemother* **57**, 1-3 (2006).

- 645 15. L. W. Roberts *et al.*, Integrating multiple genomic technologies to
646 investigate an outbreak of carbapenemase-producing *Enterobacter*
647 *hormaechei*. *Nat Commun* **11**, 466 (2020).
- 648 16. S. Corvec *et al.*, AmpC cephalosporinase hyperproduction in *Acinetobacter*
649 *baumannii* clinical strains. *J Antimicrob Chemother* **52**, 629-635 (2003).
- 650 17. S. Quainoo *et al.*, Whole-Genome Sequencing of Bacterial Pathogens: the
651 Future of Nosocomial Outbreak Analysis. *Clin Microbiol Rev* **30**, 1015-
652 1063 (2017).
- 653 18. J. C. Kwong *et al.*, Translating genomics into practice for real-time
654 surveillance and response to carbapenemase-producing
655 *Enterobacteriaceae*: evidence from a complex multi-institutional KPC
656 outbreak. *PeerJ* **6**, e4210 (2018).
- 657 19. Y. Jiang *et al.*, The Cost of Responding to an *Acinetobacter* Outbreak in
658 Critically Ill Surgical Patients. *Surg Infect (Larchmt)* **17**, 58-64 (2016).
- 659 20. Z. Sadique, B. Lopman, B. S. Cooper, W. J. Edmunds, Cost-effectiveness of
660 Ward Closure to Control Outbreaks of Norovirus Infection in United
661 Kingdom National Health Service Hospitals. *J Infect Dis* **213 Suppl 1**, S19-
662 26 (2016).
- 663 21. D. Marchaim *et al.*, Surveillance cultures and duration of carriage of
664 multidrug-resistant *Acinetobacter baumannii*. *J Clin Microbiol* **45**, 1551-
665 1555 (2007).
- 666 22. A. J. Rodriguez-Acevedo, X. J. Lee, T. M. Elliot, L. G. Gordon, Hospitalization
667 costs for patients colonized with carbapenemase-producing
668 *Enterobacteriales* during an Australian outbreak. *J Hosp Infect*, (2020).
- 669 23. S. R. Harris *et al.*, Evolution of MRSA during hospital transmission and
670 intercontinental spread. *Science* **327**, 469-474 (2010).
- 671 24. A. C. Schurch, S. Arredondo-Alonso, R. J. L. Willems, R. V. Goering, Whole
672 genome sequencing options for bacterial strain typing and epidemiologic
673 analysis based on single nucleotide polymorphism versus gene-by-gene-
674 based approaches. *Clin Microbiol Infect* **24**, 350-354 (2018).
- 675 25. S. J. Peacock, J. Parkhill, N. M. Brown, Changing the paradigm for hospital
676 outbreak detection by leading with genomic surveillance of nosocomial
677 pathogens. *Microbiology* **164**, 1213-1219 (2018).
- 678 26. J. Stimson *et al.*, Beyond the SNP Threshold: Identifying Outbreak Clusters
679 Using Inferred Transmissions. *Mol Biol Evol* **36**, 587-603 (2019).
- 680 27. A. Kramer, I. Schwebke, G. Kampf, How long do nosocomial pathogens
681 persist on inanimate surfaces? A systematic review. *BMC Infect Dis* **6**, 130
682 (2006).
- 683 28. A. C. o. S. a. Q. i. H. C. (ACSQHC), "AURA 2019: third Australian report on
684 antimicrobial use and resistance in human health," (Sydney, 2019).
- 685 29. D. E. Wood, S. L. Salzberg, Kraken: ultrafast metagenomic sequence
686 classification using exact alignments. *Genome Biol* **15**, R46 (2014).
- 687 30. A. Bankevich *et al.*, SPAdes: a new genome assembly algorithm and its
688 applications to single-cell sequencing. *J Comput Biol* **19**, 455-477 (2012).
- 689 31. A. Gurevich, V. Saveliev, N. Vyahhi, G. Tesler, QUASt: quality assessment
690 tool for genome assemblies. *Bioinformatics* **29**, 1072-1075 (2013).
- 691 32. T. Seemann, Snippy: fast bacterial variant calling from NGS reads. (2015).
- 692 33. T. Seemann, mlst: <https://github.com/tseemann/mlst>. "This publication
693 made use of the PubMLST website (<https://pubmlst.org/>) developed by

- 694 Keith Jolley (Jolley & Maiden 2010, BMC Bioinformatics, 11:595) and sited
695 at the University of Oxford. The development of that website was funded
696 by the Wellcome Trust".
- 697 34. S. G. Bartual *et al.*, Development of a multilocus sequence typing scheme
698 for characterization of clinical isolates of *Acinetobacter baumannii*. *J Clin*
699 *Microbiol* **43**, 4382-4390 (2005).
- 700 35. T. Seemann, Abricate, Github <https://github.com/tseemann/abricate>.
- 701 36. E. Zankari *et al.*, Identification of acquired antimicrobial resistance genes.
702 *J Antimicrob Chemother* **67**, 2640-2644 (2012).
- 703 37. A. Carattoli *et al.*, In silico detection and typing of plasmids using
704 PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob*
705 *Agents Chemother* **58**, 3895-3903 (2014).
- 706 38. M. J. Sullivan, N. K. Petty, S. A. Beatson, Easyfig: a genome comparison
707 visualizer. *Bioinformatics* **27**, 1009-1010 (2011).
- 708 39. N. F. Alikhan, N. K. Petty, N. L. Ben Zakour, S. A. Beatson, BLAST Ring
709 Image Generator (BRIG): simple prokaryote genome comparisons. *BMC*
710 *Genomics* **12**, 402 (2011).
- 711 40. A. Rambaut, FigTree. (2009).
- 712 41. M. Inouye *et al.*, SRST2: Rapid genomic surveillance for public health and
713 hospital microbiology labs. *Genome Med* **6**, 90 (2014).
- 714 42. S. K. Gupta *et al.*, ARG-ANNOT, a new bioinformatic tool to discover
715 antibiotic resistance genes in bacterial genomes. *Antimicrob Agents*
716 *Chemother* **58**, 212-220 (2014).
- 717 43. B. D. Ondov *et al.*, Mash: fast genome and metagenome distance
718 estimation using MinHash. *Genome Biol* **17**, 132 (2016).
- 719 44. T. J. Carver *et al.*, ACT: the Artemis Comparison Tool. *Bioinformatics* **21**,
720 3422-3423 (2005).
- 721 45. F. Compain *et al.*, Targeting relaxase genes for classification of the
722 predominant plasmids in Enterobacteriaceae. *Int J Med Microbiol* **304**,
723 236-242 (2014).
- 724 46. S. Koren *et al.*, Canu: scalable and accurate long-read assembly via
725 adaptive k-mer weighting and repeat separation. *Genome Res* **27**, 722-736
726 (2017).
- 727 47. T. Carver, S. R. Harris, M. Berriman, J. Parkhill, J. A. McQuillan, Artemis: an
728 integrated platform for visualization and analysis of high-throughput
729 sequence-based experimental data. *Bioinformatics* **28**, 464-469 (2012).
- 730 48. B. J. Walker *et al.*, Pilon: an integrated tool for comprehensive microbial
731 variant detection and genome assembly improvement. *PLoS One* **9**,
732 e112963 (2014).
- 733 49. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-
734 Wheeler transform. *Bioinformatics* **25**, 1754-1760 (2009).
- 735 50. T. Seemann, Prokka: rapid prokaryotic genome annotation. *Bioinformatics*
736 **30**, 2068-2069 (2014).
- 737 51. A. M. Varani, P. Siguier, E. Gournayre, V. Charneau, M. Chandler, ISSaga is
738 an ensemble of web-based methods for high throughput identification
739 and semi-automatic annotation of insertion sequences in prokaryotic
740 genomes. *Genome Biol* **12**, R30 (2011).

- 741 52. M. J. Chaisson, G. Tesler, Mapping single molecule sequencing reads using
742 basic local alignment with successive refinement (BLASR): application
743 and theory. *BMC Bioinformatics* **13**, 238 (2012).
744 53. D. P. Miller, Q. Wang, A. Weinberg, R. J. Lamont, Transcriptome analysis of
745 *Porphyromonas gingivalis* and *Acinetobacter baumannii* in polymicrobial
746 communities. *Mol Oral Microbiol* **33**, 364-377 (2018).
747 54. A. P. Tomaras, C. W. Dorsey, R. E. Edlmann, L. A. Actis, Attachment to and
748 biofilm formation on abiotic surfaces by *Acinetobacter baumannii*:
749 involvement of a novel chaperone-usher pili assembly system.
750 *Microbiology* **149**, 3473-3484 (2003).
751

752

753

754 **Declarations:**

755

756 *Ethics approval and consent to participate:*

757 Ethics approval was provided by the RBWH HREC as a low-risk study with waiver of
758 consent (HREC/16/QRBW/581).

759

760 *Consent for publication:*

761 Not applicable.

762

763 *Availability of data and materials:*

764 The datasets supporting the conclusions of this article are available in the short read
765 archive (SRA) repository, under the following Bioprojects: the complete genomes for
766 MS14413 (GenBank: CP054302.1) and MS14393 (GenBank: CP054303-CP054305)
767 have been deposited under the Bioprojects PRJNA631347 and PRJNA631348,
768 respectively. All isolate Illumina sequencing reads have been deposited under the
769 Bioproject PRJNA631491. All metagenomic Illumina sequencing reads have been
770 deposited under the Bioproject PRJNA631351.

771

772 *Competing interests:*

773 PNAH has received research grants from MSD, Sandoz and Shionogi Ltd, outside of
774 the submitted work, and speaker's fees from Pfizer paid to The University of
775 Queensland. DLP reports receiving grants and personal fees from Shionogi and Merck
776 Sharp and Dohme and personal fees from Pfizer, Achaogen, AstraZeneca, Leo
777 Pharmaceuticals, Bayer, GlaxoSmithKline, Cubist, Venatorx, and Accelerate. JL has
778 received personal fees from Pfizer and MSD and grants from MSD paid to The
779 University of Queensland. The other authors have no conflicts of interest to declare.

780

781 *Funding:*

782 LWR was supported by an Australian Government Research Training Program (RTP)
783 Scholarship. SAB, PNAH and MAS were supported by fellowships from the Australian
784 National Health and Medical Research Council (GNT1090456, GNT1157530 and
785 GNT1106930, respectively). The work was supported by VC Strategic Initiative
786 Funding from The University of Queensland (2016-2018) and grants from the
787 Queensland Genomics Health Alliance (now Queensland Genomics), Queensland
788 Health, Queensland Government (<https://queenslandgenomics.org/projects/round-2/infectious-disease-portfolio/#healthcare-associated-infections-project>). The funders
789 had no role in study design, data collection and interpretation, or the decision to submit
790 the work for publication.

792

793 *Authors' contributions:*

794 LWR, PNAH and SAB designed study. PNAH, GRN, NG, JM and JL coordinated
795 patient inclusion and isolate collection from the hospital. LWR and TH collected
796 environmental samples. TH and KH coordinated infection control response. LWR,

797 BMF and WL performed experiments. LWR, SAB, BMF and PNAH prepared clinical
798 reports. All authors contributed to the interpretation of results. SAB, PNAH, MAS and
799 DP supervised aspects of the project and provided essential expert analysis. LWR,
800 PNAH, SAB, WL, and TH wrote the manuscript. All authors read and approved the
801 final manuscript.

802

803 *Acknowledgements:* We acknowledge all staff at the Royal Brisbane and Women's
804 Hospital and Pathology Queensland who were involved in patient care and the clinical
805 response to the outbreak described in this study. We acknowledge the facilities, and the
806 scientific and technical assistance of staff at the Australian Centre for Ecogenomics
807 Sequencing Facility (The University of Queensland (UQ)) and the Public Health
808 Microbiology Laboratory at Queensland Forensic and Scientific Services (Queensland
809 Health). We thank Thomas Cuddihy (QFAB Bioinformatics and Research Computing
810 Centre, UQ) for high-performance computing support. We thank Kate Peters (Schembri
811 lab, UQ) For technical assistance preparing genomic DNA.

812

813

814

815

816

817

818

819

820

821

822

823

824 **Table 1: CR-Ab MICs and AB resistance genes:** Table only shows select representative isolates as all
 825 CR-Ab were found to have the same AB resistance gene profile and MIC data. Colours represent
 826 mechanism of detection: blue = Etest MIC, Green = Disk diffusion zone diameter, Orange = Vitek2,
 827 Grey = Resfinder (accessed Aug 2017).

Strain		MS8413	MS8419	MS8436	MS8442	MS8441
Patient		4	5	6	7	8
Site		Leg wound	ETA	Tissue buttock	Wound Swab	Rectal Swab
Colistin	Colistin	0.125	0.25	0.25	0.125	0.5
Carbapenem	Mero	32	>32	>32	>32	>32
	Imi	>32	>32	n.t	>32	n.t
	Erta	>32	>32	>32	>32	>32
Beta-lactam and Cephalosporins	Sulb	32	32	64	32	64
	MER	R	R	R	R	R
	TIM	R	R	R	R	R
	TAZ	R	R	R	R	R
	CRO	R	R	R	R	R
	CAZ	R	R	R	R	R
	FEP	R	R	R	R	R
	KZ	R	R	R	R	R
	Azt	6mm R	6mm R	n.t	6mm R	n.t
	CTZ/TAZ	>256	>256	128	16	96
	CAZ/AVI	16mm R	17mm R	18mm R	15mm R	18mm R
	blaADC-25	+	+	+	+	+
	blaOXA-23	+	+	+	+	+
	blaOXA-66	+	+	+	+	+
Aminoglycosides	Amikacin	>256	>256	>256	>256	>256
	GENT	R	R	R	R	R
	TOB	R	R	R	R	R

	Aph(3')-Ic-1	+	+	+	+	+
	aadA1	+	+	+	+	+
	armA	+	+	+	+	+
Quinolones	CIP	R	R	R	R	R
	NOR	R	R	R	R	R
Trimethoprim/ Sulphonamide	TMP	R	R	R	R	R
	SXT	R	R	R	R	R
	Sul1	+	+	+	+	+
	Sul2	+	+	+	+	+
Tigecycline	Tige	2	2	2	2	4
Chloramphenicol	Chloro	6mm R	6mm R	n.t	6mm R	n.t
	catB8	+	+	+	+	+
Fosfomicin	Fosfo	256	512	n.t	128	n.t
Tetracycline	Doxy	4	4	2	2	2
Macrolides	mph(E)_3	+	+	+	+	+
	msr(E)_4	+	+	+	+	+
Streptomycin	strA	+	+	+	+	+
	strB	+	+	+	+	+

828 n.t = not tested

829 Mero = Meropenem, Tige = Tigecycline, Sulb = Sulbactam, CTZ/TAZ = Ceftolozane/tazobactam,

830 CAZ/AVI = Ceftazidime/avibactam, Chloro = Chloramphenicol, Fosfo = Fosfomicin, Azt =


831 Aztreonam, Erta = Ertapenem, Doxy = Doxycycline, Imi = Imipenem, KZ = Cephazolin, TMP =

832 Trimethoprim, SXT = Co-trimoxazole, GENT = Gentamicin, TOB = Tobramycin, CRO = Ceftriaxone,

833 CAZ = Ceftazidime, FEP = Cefepime, TAZ = Piperacillin/tazobactam, CIP = Ciprofloxacin, NOR =

834 Norfloxacin, MER = Meropenem, TIM = Ticarcillin/clavulanate

835



836

837 **Figure 1: Patient relationship matrix describing 2016 outbreak of CR-Ab:** [A] Each circle

838 represents a patient, where the size of the circle correlates to the number of isolates from that patient.

839 Colours correspond to bacterial species. Straight lines connecting circles represent patients with


840 identical isolates at the core genome level (and as such directionality of transmission cannot be

841 inferred). Lines with arrows (coloured by species) represent predicted direction of transmission based

842 on the accumulation of SNPs between patients' isolates. Circular arrows represent changes in

843 individual patient's isolates, [B] timeline of patient samples, as well as location and surgery dates.

844



845

846 **Figure 2: large ~41 kb tandem duplication found in MS14413:** Duplication of part of the capsule (K)

847 region in the MS14413 complete genome (top line), resulting in 3 chromosomal copies of Tn2006 (third

848 copy at alternate locus). This duplication appears to have arisen in some of the index patient isolates, but


849 not other isolates involved in the outbreak (e.g. MS14407 concatenated draft genome, central line). The

850 wzy gene in the capsule region was found to be interrupted by an ISAbal25 element, however a secondary

851 wzy gene was identified at the start of the capsule region. Neither the ISAbal25 insertion or secondary

852 wzy gene is found in the KL12 capsule locus of *A. baumannii* strain D36 (bottom line).

853



854

855 **Figure 3: Ongoing CR-Ab surveillance from 2016-2018:** [A] timeline of CR-Ab cases and dates of
 856 environmental swabbing between 2016-2018 [B] Relationship matrix of all CR-Ab isolates related to the
 857 initial outbreak. Col-R = predicted colistin resistance via mutation in *pmrB*. Isolates within the same
 858 circle are identical at the core genome. Branches represent 1 SNP difference (except where specified).
 859 Isolates from the original 2016 outbreak are in yellow. Purple isolates were collected in late 2016-2017.
 860 Isolates in blue were collected in 2018. Isolate M88825 was isolated from an Antechamber environment
 861 in 2018 and found to be identical at the core SNP level to M7120, isolated in August 2017.

862

863




864

865 **Figure 4: Burns bath 3 floor trap:** an example of the biomass uncovered under the floor trap in a Burns

866 Unit bathroom. Areas of high biomass (such as this one) were targeted for environmental screening.

867

868



869

870 **Figure 5: Clustering of MAGs with outbreak strains:** Mid-point rooted core genome SNP
871 phylogenetic tree contextualising the metagenome assembled genomes (MAGs) with *de novo* assemblies
872 of the outbreak strains and publicly available complete *A. baumannii* genomes (yellow) showing
873 clustering of the MAGs (blue) within the outbreak clade (pink).

874

875

876

877

878

879

880

881

882

883

Supplementary Material

884

885 Supplementary Methods:

886

887 *Illumina sequencing:*

888 All isolates collected between May-September 2016 (and all historically collected
889 isolates) were sequenced at the Australian Centre for Ecogenomics (ACE) Sequencing
890 Service, University of Queensland, Brisbane, Australia. DNA was quantitated using
891 Qubit and libraries prepared using Nextera XT library prep (Illumina) with Nextera
892 XT/V2 Indexes, as per manufacturer's instructions. Resulting libraries were quantitated
893 with either qPCR or TapeStation, pooled and each sample loaded onto either 1/100th or
894 1/200th of a flow cell and sequenced on the NextSeq (Illumina) using a 2 x 150bp High
895 Output V2 kit.

896

897 All subsequent isolates (from October 2016 onwards) were sequenced at the Public
898 Health Microbiology Laboratory at Queensland Forensic and Scientific Services,
899 Brisbane, Australia. All libraries were prepared using the Nextera XT DNA preparation
900 kit (Illumina) and sequencing was performed on a NextSeq 500 (Illumina) with
901 2x150bp chemistry, NextSeq Midoutput kit v2.5.

902

903 *Bioinformatic analysis for clinical reporting*

904 Methodologies for bioinformatic analysis and communication of Illumina WGS data
905 during primary outbreak in 2016 (June 22, July 16, Aug 2, Aug 29) are outlined below:

906

907 Quality control and *de novo* assembly of Illumina WGS data and comparative genome
908 analysis were carried out as described in the main document. Raw reads were analysed
909 using Nullarbor (<https://github.com/tseemann/nullarbor>) to determine MLST,
910 antibiotic resistance gene profile, and core SNP phylogeny using species-specific
911 reference sequences. Closest publicly available complete genomes were chosen as
912 reference sequences where available (*Acinetobacter baumannii* Global Clone (GC) 2
913 strain 1656-2 (GI:384129960); *Klebsiella pneumoniae subsp. pneumoniae* MGH 78578
914 (GI:150953431); *Serratia marcescens* WW4 (GI:448239774); *Pseudomonas*
915 *aeruginosa* PA1R (GI:558665962). For *Enterobacter cloacae* the reference was the
916 concatenated draft genome of *Enterobacter cloacae* Ecl1 (GenBank: JRFQ01000000;
917 now reassigned as *E. hormaechei*), an ST90 strain isolated from a burns patient at the
918 RBWH ICU in 2015. Antibiotic resistance gene content and MLST was further checked
919 using *srst2*(41) against the ARG-ANNOT(42) database and the Oxford MLST
920 scheme(34), respectively. Plasmid Inc Typing was done based on the relaxase gene as
921 described by Compain *et al.* (45).

922

923 SNP differences between strains were determined using Nesoni
924 (<https://github.com/Victorian-Bioinformatics-Consortium/nesoni>) and evolutionary
925 relationships were determined shown as phylograms or Eburst-style matrices in which
926 nodes of identical isolates were separated by branches representing one or more core
927 SNP differences radiating from a founder (index) node. This format provided
928 consistency across reports, enabling a progressive expansion of the display figure from
929 a common anchor as each WGS batch was reported, in contrast to phylograms where
930 topology and isolate order could change substantially as the data was updated. For
931 example Supplementary Figure 2 is a close approximation of the CR-Ab tree reported

932 in August 2016 and forms the anchor to Figure 3B which shows all ST1050 CR-Ab in
933 the study.

934 Methodologies used for subsequent reports (Nov 4 2016, Mar 9 2017, Jun 20 2017, Oct
935 10 2017) were essentially the same except that the concatenated draft genome of
936 ST1050 CR-Ab MS8436 or MS14413 was used as reference sequences, Abricate (v0.6)
937 with ResFinder was used for antibiotic gene prediction, and from 2017 Nesoni
938 implemented Bowtie for alignment instead of SHRiMP.

939

940 All 2018 CR-Ab isolate genomes were initially reported to RBWH as part of an
941 Infectious Diseases demonstration project in WGS surveillance of MDR bacteria in
942 hospitals (encompassing most of this authorship group) funded by the Queensland
943 Genomics Health Alliance (now Queensland Genomics), Queensland State
944 Government, Australia.

945

946 *Pacific Biosciences sequencing:*

947 One CR-Ab isolate (MS14413) and one *K. pneumoniae* isolate (MS14393) were
948 selected for sequencing with Pacific Biosciences (PacBio) Single Molecule Real-Time
949 (SMRT) sequencing. Isolates were grown on LB agar at 37°C overnight. A single
950 colony was used to inoculate 10 ml LB broth, grown overnight at 37°C (shaking 250
951 rpm). DNA was extracted using the UltraClean[®] Microbial DNA Isolation Kit (MO
952 BIO Laboratories) as per manufacturer's instructions. 20kb SMRTbell libraries were
953 prepared using P6 polymerase and C4 sequencing chemistry with 7kb size selection
954 with BluePippin. Final polymerase bound libraries were sequenced using 1 SMRT cell
955 each on a PacBio RSII instrument at the University of Queensland Centre for Clinical
956 Genomics, Translational Research Institute, Brisbane, Australia.

957

958 *Pacific Biosciences genome assembly and annotation:*

959 PacBio genomes were assembled using Canu(46) v1.3 and manually closed using
960 Artemis(47). A large duplicated region of ~40 kb was identified in the CR-Ab isolate
961 and resolved using read-mapping and PCR at unique borders of the duplication (see
962 below). The SMRT Analysis suite (v7.0.1.66975) was used to generate methylated
963 motif summaries and polished assemblies using the PacBio reads. Indels were further
964 corrected with Pilon(48) v1.22 using the trimmed Illumina reads mapped to the
965 assembly using BWA(49) v0.7.16a-r1181. Complete PacBio genomes were annotated
966 using Prokka(50) v1.12-beta. Insertion sequences were identified using ISSaga(51).
967 Frameshifts were corrected by manually inspecting read pileup at suspected positions
968 identified using NCBI microbial genome submission check
969 (<https://www.ncbi.nlm.nih.gov/genomes/frameshifts/frameshifts.cgi>).

970

971 *Closing the genome of CR-Ab strain MS14413:*

972 *De novo* assembly of the CR-Ab strain MS14413 PacBio reads using Canu resulted in
973 two contigs: one large contig (~4 Mb) and one small contig (~65 kb). The large contig
974 corresponded to the CR-Ab chromosome and could be circularized. Comparison of both
975 contigs to each other using the Artemis Comparison Tool (ACT) determined that the
976 smaller contig matched the ends of the chromosome perfectly except for a duplicated
977 ~4.8 kb region. Rearrangement of this region onto the contig ends and re-mapping of
978 both PacBio and Illumina reads to the chromosome (using BWA and blasr,
979 respectively) resolved the ~4.8 kb region but simultaneously identified approximately
980 twice as much read depth across a ~40 kb region on the chromosome, indicative of a
981 large collapsed repeat in our initial assembly. Comparative analysis of the smaller

982 contig (using ACT) followed by PCR at unique borders of the suspected tandem
983 duplication (Fig. S1, Table S1) enabled resolution of the region as two copies of ~41
984 kb. Further mapping with both the Illumina and PacBio reads (using BWA(49) and
985 blasr(52), respectively) confirmed the tandem duplication, which has been included in
986 the complete genome of CR-Ab strain MS14413 (GenBank: CP054302.1).

987

988 **Supplementary Results:**

989

990 ~40 kb tandem duplication in CR-Ab genome

991 PacBio sequencing of CR-Ab isolate MS14413 identified a large tandem duplication of
992 approximately ~40 kb, encompassing Tn2006 as well as part of the capsule (K) region
993 (Figure 3, main text). Analysis of the other CR-Ab isolates using the Illumina *de novo*
994 assemblies found evidence for this duplication in only two related colistin resistant
995 isolates from the index patient (MS14413 [PacBio] and MS14402), suggesting that this
996 duplication arose once and was maintained by a sub-population of CR-Ab within this
997 patient for at least 36 days. The effect of this duplication on fitness is as of yet unknown.

998

999 Transmission of *K. pneumoniae* parallel to CR-Ab transmission

1000 Ten ESBL-producing *K. pneumoniae* isolates were collected from 5 patients during the
1001 outbreak and were all found to be ST515. Nine of the ten isolates differed by less than
1002 10 core SNPs, indicating direct transmission within the ICU ward (Fig. S8). A single
1003 isolate from the index patient (MS14418) was found to have an additional 61 core
1004 SNPs, consistent with a hypermutator phenotype. Indeed, further investigation of this
1005 isolate found an in-frame 9 bp deletion in *mutH*, resulting in the loss of 3 amino acids

1006 from this protein (Fig. S9). The exact mechanism behind this deletion in *mutH* and its
1007 relationship to the hypermutator phenotype remains to be further elucidated.

1008

1009 All ESBL-positive *K. pneumoniae* isolates had identical antibiotic resistance gene
1010 profiles, including the ESBL gene *bla*_{CTX-M-15}, other β -lactamases (*bla*_{TEM}, *bla*_{OXA-1})
1011 and the aminoglycoside resistance gene *aac(6')Ib-cr*. Two isolates from the index
1012 patient (MS14393 and MS14418) developed resistance to carbapenems, which was
1013 likely due to an *IS10R* insertion in the outer membrane porin gene *ompK36* (Fig. S8).
1014 Isolate MS14433 (from patient 16) also contained an *IS10R* inserted into *ompK36*,
1015 however the insertion was found to be close to the 5' boundary of the *ompK36* gene
1016 and based on *in silico* analysis there was no evidence that it affected the function of the
1017 resulting protein. Isolate MS14393 (from the index patient) also possessed a nonsense
1018 mutation in the antibiotic resistance protein repressor gene *marR*, which could
1019 contribute to its overall resistance to antibiotics.

1020

1021 The *K. pneumoniae* isolates carry two plasmids involved in antibiotic resistance and
1022 virulence

1023 A single *K. pneumoniae* isolate from the index patient (MS14393) was sequenced using
1024 PacBio long-read sequencing to generate a high-quality reference genome, consisting
1025 of a 5,492,431 bp chromosome, a 216,803 bp IncF plasmid (pMS14393A), and a
1026 125,232 bp IncA/C plasmid (pMS14393B). Most of the antibiotic resistance genes
1027 resided on the IncA/C plasmid in two main loci (Fig. S6). The larger IncF plasmid did
1028 not contain any antibiotic resistance genes, but did harbor several heavy metal
1029 resistance operons, including resistance to copper, arsenic and mercury (fig. S10).

1030

1031 Genomic factors affecting adhesion, biofilm formation and motility

1032 Analysis of SNP differences between the ST1050 CR-Ab isolates found a single SNP
1033 resulting in a reversion of a nonsense mutation to a functional amino acid codon in the
1034 gene *filB* within the *fil* operon; a putative type 3 filamentous fimbriae. This reversion
1035 was obscured in the Snippy analysis, as one isolate (MS14422) was heterozygous at
1036 this position, resulting in it being masked from the core SNP analysis. This reversion
1037 corresponded to the latter half of the outbreak, including all CR-Ab isolates taken after
1038 the 4th of July 2016 (with the exception of MS14413 [6/7/16], MS14438 [12/9/16] and
1039 SS17M5036 [17/5/17]) (Fig. S4). As stated, MS14422 appeared to have both alleles at
1040 this position and represents either (i) a transitioning population reverting from a
1041 functional codon back to a stop codon, or (ii) a mixed population of both allele types.
1042 Due to the unusual nature of this nonsense mutation reversion, we downloaded all
1043 available complete publicly available *A. baumannii* strains from NCBI (accessed 15-
1044 11-2018) and inspected the *filB* region. This analysis showed that there were multiple
1045 *A. baumannii* strains with disrupted *filB* genes, caused not only by nonsense mutations,
1046 but also interruption by insertion sequences and frameshift mutations (Fig. S4). Many
1047 of the publicly available strains also appeared to have functional *filB* genes, with
1048 reversion from a stop codon to a functional gene possible based on the phylogeny.
1049 While not much is known about this fimbriae in *A. baumannii*, several of the genes
1050 within this operon were shown to be down-regulated in community settings(53),
1051 suggesting that it may not be required in biofilms or stable bacterial populations. It is
1052 possible that it increases survivability or transmission throughout the environment,
1053 however further work is required to determine the phenotypic qualities of this mutation.
1054

1055 Conversely, and IS*Aba125* element was identified upstream of the *csu* operon in the
1056 complete genome of MS14413. The *csu* operon is a well-characterized chaperone-usher
1057 pili assembly system involved in biofilm formation(54). It is possible that this insertion
1058 sequence (IS) is driving enhanced expression of this operon, promoting adhesion to
1059 abiotic surfaces and encouraging biofilm formation. Unfortunately, due to the nature of
1060 the draft *de novo* assemblies derived from short-read sequencing, we were unable to
1061 fully characterise this insertion in all isolates. Further work is required to completely
1062 characterise the position of this IS in all outbreak isolates.

1063

1064 No transmission of *P. aeruginosa* or *S. marcescens* from the index patient was
1065 observed

1066 *P. aeruginosa* isolates from the index patient were found to be ST979 and all carried 5
1067 antibiotic resistance genes (*aph(3')-IIb*, *bla_{OXA-50}*, *bla_{PAO}*, *catB7* and *fosA*)
1068 (Supplementary Table 2). The final *P. aeruginosa* isolate from the index patient
1069 (MS14412) was found to be more resistant to carbapenems, likely due to a nonsense
1070 mutation in the outer membrane porin *oprD*, as well as a non-conservative amino acid
1071 change in the response regulator *parR*. Initial *S. marcescens* isolates appeared to only
1072 carry *aac(6')-Ic*, *bla_{SRT-2}*, *oqxB*, and *qnrE*. However, later acquisition of an IncHI2
1073 plasmid in two *S. marcescens* isolates was associated with large number of additional
1074 resistance genes, including the ESBL *bla_{CTX-M-15}* (Supplementary Table 3).

1075

1076

1077

1078

1079

1080 **Supplementary Tables:**

1081

1082 **Supplementary Table 1:** Primers used to resolve large duplication in CR-Ab isolate MS14413

Name	Sequence	Length	GC	Tm
8076_A1_border1_F	TCCCGGCACTTAACTTACGT	20	50	63.7
8077_A2_wbuB_R	CGGCCAATCACGATCAGATG	20	55	69.2
8078_B1_OXA23_F	TCTGTATTTGCGCGGCTTAG	20	50	65.4
8079_C1_border2_R	TTAGCTCCCCACACTGAG	20	55	63.4

1083

1084

1085 **Supplementary Table 2:** Antibiotic resistance genes in *P. aeruginosa* isolates from the index patient:

1086 tick denotes presence

1087

	aph(3')-IIb_1	blaOXA-50_1	blaPAO_4	catB7_1	fosA_1
MS14395	✓	✓	✓	✓	✓
MS14399	✓	✓	✓	✓	✓
MS14403	✓	✓	✓	✓	✓
MS14412	✓	✓	✓	✓	✓

1088

1089

1090

1091

1092

1093 **Supplementary Table 3:** Antibiotic resistance genes in *S. marcescens* isolates from the index patient:
 1094 tick denotes presence; number denotes %nucleotide coverage (where two numbers separated by a comma
 1095 represents a split blast result)

	QnrB1_1	aac(3)-IIa_1	aac(6)-Ic_1	aac(6')Ib-cr_1	aadA1_1	blaCTX-M-15_23	blaOXA-1_1	blaSRT-2_1	blaTEM-1B_1	catA1_1	dfr/A14_1	oqxB_1	qnrE_1	strA_4	strB_1	sul2	tet(A)_4
MS8415			✓					✓				✓	✓				
MS14404*	✓		✓	✓	✓	✓	51.74, 19.01	✓	✓	65.91	✓	✓	✓	✓	✓	✓	✓
MS8416*	✓	✓	✓	✓	✓	✓	40.07, 52.23	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

1096 * Contain IncHI2 plasmid

1097

1098

1099 **Supplementary table 4: Positive culture and sequencing results from 2018 environmental sampling**

Sample	Isolation date	Culture result	Sequencing result	# reads total in sample	# reads mapped to MS14413	% reads	# Contigs in <i>de novo</i> assembly
R5666	16/08/2018	ST1050 CR-Ab	No CR-Ab	n/a	n/a	n/a	n/a
R5515	26/07/2018	No CR-Ab	ST1050 CR-Ab	43582216	444810	1.0%	4173
R5510	26/07/2018	No CR-Ab	ST1050 CR-Ab	51421258	3134890	6.1%	8125
R5863	02/10/2018	No CR-Ab	ST1050 CR-Ab	41402234	369031	0.9%	10011
R5864	02/10/2018	ST1050 CR-Ab	ST1050 CR-Ab	38635392	2634975	6.8%	1326

1100

1101

1102


1103

1104

1105

1106 **Supplementary Figures:**

1107




1108

1109 **Supplementary Figure 1: Primer binding regions to resolve large duplication in CR-Ab isolate**

1110 MS14413 (not to scale)

1111

1112



1113

1114 **Supplementary Figure 2: Relationship matrix of outbreak ST1050 CR-Ab isolates from 2016:**

1115 isolates within the same circle are identical at the core SNP level. Black lines indicate 1 SNP difference,

1116 except where stated otherwise. Patient numbers denoted with “p” and the corresponding number. “Col-

1117 R” denotes isolates with colistin resistant SNPs. The yellow circle includes 15 isolates identical at the


1118 core SNP level from patients 1-9 and 12: MS14431, MS14430, MS14397 (p1); MS8410, MS8412 (p2);

1119 MS8422 (p3); MS8413 (p4); MS8419 (p5); MS8436, MS8440 (p6); MS8442 (p7) MS8441 (p8),

1120 MS14388 (p9) and MS14421 (p12).

1121 .


1122



1123

1124

1125 **Supplementary Figure 3: Comparison of outbreak ST1050 CR-Ab isolates to CR-Ab previously**
1126 **isolated from the same hospital between 2000 to early 2016:** Tree was created with Parsnp v1.2
1127 (default settings) using the draft *de novo* assemblies for the ST1050 CR-Ab as well as 17 historical CR-
1128 Ab from the same hospital. For clarity, the node representing the March-April 2016 isolates (ST930) has
1129 been removed from tree as its long branch length obscured the other nodes (see red box inset).



1130


1131 **Supplementary Figure 4: Analysis of nonsense mutation reversion in ST1050 outbreak CR-Ab and**
 1132 **complete publicly available *A. baumannii* (from NCBI): Tree built using Parsnp v1.2 (under default**
 1133 **settings) with 113 complete *A. baumannii* and the initial outbreak ST1050 CR-Ab genomes (mid-point**
 1134 **rooted). Taxa are coloured according to *filB* genotype (refer to key). Inset box shows relationship matrix**
 1135 **from Figure 3 (in main text) with nodes coloured according to *filB* genotype. SS17M414 (isolated**
 1136 **3/1/2017) also has a functional *filB* gene, however, is not displayed in the relationship matrix as it clusters**
 1137 **in the large group of 16 identical isolates.**

1138

1139

1140

1141



1142

1143 **Supplementary Figure 5: Novel AbGR11 resistance island in MS14413.** BLASTn comparison

1144 shown in grey.

1145

1146

1147

1148

1149

1150

1151

1152

1153


1154

1155


1156

[A] *K. pneumoniae* resistance genes


(i) AB resistance region 1 (15.6 kb):



(ii) AB resistance region 2 (23.8 kb):



[B] CR-Ab resistance genes



1157

1158 **Supplementary Figure 6: Resistance regions found in *K. pneumoniae* [A] and CR-Ab [B] isolates:**

1159 arrows represent CDS. Colours represent resistance genes (yellow), regulatory/efflux genes (orange),

1160 mobile elements (blue) and hypothetical genes (grey). [A] two resistance regions were found in all *K.*

1161 *pneumoniae* isolates, located on an IncA/C plasmid. [B] CR-Ab isolates were found to have three main

1162 mechanisms of resistance: (i) a large transposon Tn6279 (ABGRI3-2), (ii) a smaller transposon (Tn2006)

1163 and (iii) an *ISAba1* element upstream of the intrinsic *ampC* gene.

1164


1165

1166

1167


1168

1169



1170

1171 **Supplementary Figure 7: *wzy* gene positions in capsule (K) region:** Light blue arrows represent CDS
 1172 regions. Dark blue box represents capsule region. Outbreak CR-*Ab* isolate MS14413 was found to have
 1173 a 97% nucleotide similarity to the KL12 capsule (K) locus found in the GC1 *A. baumannii* strain D36
 1174 (GenBank:NZ_CP012952.1) except for an *ISAbal25* insertion sequence in the *wzy* gene. Further
 1175 comparison found a second *wzy* gene in the same position as in the *A. baumannii* strain BAL_097
 1176 (GenBank: KX712116).



1177

1178 **Supplementary Figure 8: Relationship matrix of ST515 *Klebsiella pneumoniae* isolates during 2016**
 1179 **outbreak and disruption of *ompK36* outer membrane porin by *IS10R*:** coloured circles correspond
 1180 to patient. Branches represent one SNP difference unless otherwise stated.

1181

MutH:

```

1  MPAIAPLASPPQSQEQLLAQARQLAGYSLGELAALAGIPIPRDLKRDKGWTGILLELWLG  60
   MPAIAPLASPPQSQEQLLAQARQLAGYSLGELA  GIPIPRDLKRDKGWTGILLELWLG
   MPAIAPLASPPQSQEQLLAQARQLAGYSLGELA  --GIPIPRDLKRDKGWTGILLELWLG

61  ASAGSKPEQDFAALGVELKTIPIDSRGRPLETTFVCVAPLTGNSGVTWESSHVRHKLQRV  120
   ASAGSKPEQDFAALGVELKTIPIDSRGRPLETTFVCVAPLTGNSGVTWESSHVRHKLQRV
   ASAGSKPEQDFAALGVELKTIPIDSRGRPLETTFVCVAPLTGNSGVTWESSHVRHKLQRV


121 LWIPVEGERTIPLAARRVGAPLLWSPDEDEERRLRMDWEELMDLIVLGEVERITARHGEV  180
   LWIPVEGERTIPLAARRVGAPLLWSPDEDEERRLRMDWEELMDLIVLGEVERITARHGEV
   LWIPVEGERTIPLAARRVGAPLLWSPDEDEERRLRMDWEELMDLIVLGEVERITARHGEV

181 LQLRPKAANSKALTEAIGARGETILTLPGRGFYLKKNFTAALLARHFLLQHD  231
   LQLRPKAANSKALTEAIGARGETILTLPGRGFYLKKNFTAALLARHFLLQHD
   LQLRPKAANSKALTEAIGARGETILTLPGRGFYLKKNFTAALLARHFLLQHD
  
```

1182

1183 **Supplementary Figure 9: Deletion of three amino acids from MutH protein in MS14418**

1184




1185

1186 **Supplementary figure 10: PacBio assembly of IncF plasmid carried by *K. pneumoniae* isolate**

1187 **MS14393**

1188

1189



1190

1191

1192 **Supplementary Figure 11: Metagenomic read abundance profiles of environmental surveillance**

1193 **samples.** Each column shows the relative abundance of paired-end reads for each environmental sample

1194 that were classified at a bacterial genus level by comparing against a database of bacterial genomes from

1195 RefSeq. Only bacterial genera with a relative abundance >0.5% are shown as distinct. Genera with an

1196 abundance of <0.5% are grouped together as “Other” (grey). Black boxes outlined in black represent

1197 abundance of “Acinetobacter”.

1198

1199

1200

1201


1202

1203

1204

1205

Scatterplot of CR-Ab cases from May 2016 to May 2020



1206

1207 **Supplementary Figure 12: Incidence of ST1050 CR-Ab cases from the time of the initial outbreak**
1208 **until May 2020.**

1209

1210

1211 [Supplementary data 1: supplementary_data_1.xlsx](#)

1212 [Supplementary report 1: supplementary_report_1.pdf](#)

1213 [Supplementary report 2: supplementary_report_2.pdf](#)

1214 [Movie S1 – supplementary_file_5.mp4](#)

1215